ClinicalTrials.gg

Program

Proteasome Inhibitor SHY-ONC6

Its studies are mostly in Triple Negative Breast Neoplasms, led by SHY Therapeutics.

Furthest: phase 1, since Jul 1, 20261 company-led study, 1 open or runningNext primary completion: May 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SHY Therapeutics11 open or runningphase 1since Jul 1, 2026Jul 1, 2026May 15, 2027phase 1 · NCT07705334

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2026First study: phase 1 study in Triple Negative Breast NeoplasmsFirst studyNCT07705334 · 30 planned · United States

Ahead

  1. May 15, 2027Primary completion: phase 1 study in Triple Negative Breast NeoplasmsNCT07705334

TargetBeta

SERPINA1 →read by rule
“An orally bioavailable small molecule proteasome inhibitor (PI), ”NCIt, by rule

Other programs on SERPINA1

ProgramCompanyFurthest phaseStudies
ensitrelvirruleShionogiphase 35
efdoralprin alfaSanofiphase 22
CTX460rulecrispr-therapeuticsphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07705334Triple Negative Breast Neoplasms · United States1RecruitingMay 15, 202730

How it is read

Names in the registry

  • “SHY-ONC6”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.